What is CytomX Therapeutics's G&A?

CytomX Therapeutics (CTMX) reported G&A of $10.69M in Q1 2026.

How has CytomX Therapeutics's G&A changed year-over-year?

CytomX Therapeutics's G&A increased by 13.4% year-over-year, from $9.43M to $10.69M.

What is the long-term trend for CytomX Therapeutics's G&A?

Over 4 years (2021 to 2025), CytomX Therapeutics's G&A has grown at a -6.6% compound annual growth rate (CAGR), from $39.16M to $29.84M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

CytomX Therapeutics CTMX G&A

G&A at other companies

Janux TherapeuticsJANX

$11.13M+13.1%

Allogene TherapeuticsALLO

$14.09M-6.0%

Vor BiopharmaVOR

$17.57M+167%

Design Therapeutics, Inc.DSGN

$5.33M+5.7%

ImmunomeIMNM

$12.95M+21.1%

Arcus BiosciencesRCUS

$29M+3.6%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's G&A?: CytomX Therapeutics (CTMX) reported G&A of $10.69M in Q1 2026.
How has CytomX Therapeutics's G&A changed year-over-year?: CytomX Therapeutics's G&A increased by 13.4% year-over-year, from $9.43M to $10.69M.
What is the long-term trend for CytomX Therapeutics's G&A?: Over 4 years (2021 to 2025), CytomX Therapeutics's G&A has grown at a -6.6% compound annual growth rate (CAGR), from $39.16M to $29.84M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.